About Neurocrine

Our Company

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. The Company’s three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson’s patients; and INGREZZA™ (valbenazine), a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette Syndrome. INGREZZA (valbenazine) capsules was approved by the FDA on April 11, 2017 for the treatment of adults with tardive dyskinesia and is currently commercialized by Neurocrine in the United States.

Research and Development Programs

Neurocrine’s research group continues to advance novel small molecule compounds into clinical development. Neurocrine scientists are focusing on developing small molecule antagonists against G-protein coupled receptors. Our scientists possess the skills and experience necessary to bring compounds from basic research concepts to drug candidate stage. Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine’s chemists, pharmacologists and biologists strive to create new solutions to unmet medical problems.

Neurocrine Biosciences Corporate Information

The Company’s common stock is traded on the Nasdaq Global Select Market System under the symbol “NBIX”

Contact Information
Investor Relations
ir@neurocrine.com
Telephone: (858) 617-7600

Neurocrine Biosciences
12780 El Camino Real
San Diego, CA 92130
Telephone: (858) 617-7600
Fax: (858) 617-7602
www.neurocrine.com